Amicus Therapeutics at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Amicus Therapeutics at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Amicus Therapeutics Cranbury, New Jersey	1 Senior Director of Scientific Evidence
amicusrx.com\|LinkedIn Subsidiary Develop and deliver transformative medicines for people living with rare diseases. Reported 2025 revenue growth of 17% at constant currency, reflecting continued expansion of its Fabry and Pompe treatments. › Reported 2025 revenue growth of 17% at constant currency, reflecting continued expansion of its Fabry and Pompe treatments. 2026-02 · source Presented new clinical and real-world data on its Fabry and Pompe treatments, reinforcing its position in these genetic-disease markets. 2026-02 · source Agreed to be acquired by BioMarin for about $4.8 billion, a deal folding its rare-disease business into a larger buyer. 2025-12 · source Source: company newsroom Q4 2025 revenue $185.2M, up 24% YoY › Growth was 20% at constant exchange rates, driven by Fabry and Pompe drug sales. · 2026-02-20 “Fourth quarter total revenues were $185.2 million up 24%, or 20% at CER.” Source: results release Currently hiring: 98 open roles › Source: careers page	Poster Thu Oct 22 4:15 pm Part of Mendelian Phenotypes Poster Thursday Session Defining the unique clinicogenomic signature of individuals carrying the A143T GLA variant, and interrogating pregnancy and menopausal health outcomes in females with A143T Exhibit & Poster Hall · Board 1140T Genotype-phenotype correlationsLysosomal diseasesPhenome-wide associationVariant interpretation

Organization

ASHG 2026 Attendance

Amicus Therapeutics

Cranbury, New Jersey

1 Senior Director of Scientific Evidence

amicusrx.com|LinkedIn

Subsidiary

Develop and deliver transformative medicines for people living with rare diseases.

Reported 2025 revenue growth of 17% at constant currency, reflecting continued expansion of its Fabry and Pompe treatments.

›

Reported 2025 revenue growth of 17% at constant currency, reflecting continued expansion of its Fabry and Pompe treatments.

2026-02 · source

Presented new clinical and real-world data on its Fabry and Pompe treatments, reinforcing its position in these genetic-disease markets.

2026-02 · source

Agreed to be acquired by BioMarin for about $4.8 billion, a deal folding its rare-disease business into a larger buyer.

2025-12 · source

Source: company newsroom

Q4 2025 revenue $185.2M, up 24% YoY

›

Growth was 20% at constant exchange rates, driven by Fabry and Pompe drug sales. · 2026-02-20

“Fourth quarter total revenues were $185.2 million up 24%, or 20% at CER.”

Source: results release

Currently hiring: 98 open roles

›

Source: careers page

Poster

Thu Oct 22
4:15 pm

Part of Mendelian Phenotypes Poster Thursday Session

Defining the unique clinicogenomic signature of individuals carrying the A143T GLA variant, and interrogating pregnancy and menopausal health outcomes in females with A143T

Exhibit & Poster Hall · Board 1140T

Genotype-phenotype correlationsLysosomal diseasesPhenome-wide associationVariant interpretation

Instantly find 20 buyers from Amicus Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction